Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer - nieuw boek

Boek bevindt zich in het datenbestand sinds 2007-08-16T08:57:27+02:00 (Amsterdam)
Detailpagina laatst gewijzigd op 2024-02-11T15:46:25+01:00 (Amsterdam)
ISBN/EAN: 9783642281600

ISBN - alternatieve schrijfwijzen:
3-642-28160-5, 978-3-642-28160-0
alternatieve schrijfwijzen en verwante zoekwoorden:
Auteur van het boek: christ klaus, pant, pantel, michail, ign, christos, sotiriou
Titel van het boek: res, min, mini, cancer, tum, cel, beyond the minimal, residu, minim, tumor

Gegevens van de uitgever

Auteur: Michail Ignatiadis; Christos Sotiriou; Klaus Pantel
Titel: Recent Results in Cancer Research; Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
Uitgeverij: Springer; Springer Berlin
254 Bladzijden
Verschijningsjaar: 2012-04-23
Berlin; Heidelberg; DE
Gedrukt / Gemaakt in
Taal: Engels
106,99 € (DE)
110,00 € (AT)
130,00 CHF (CH)
Available
XIV, 254 p.

EA; E107; eBook; Nonbooks, PBS / Medizin/Klinische Fächer; Onkologie; Verstehen; Breast cancer; Circulating nucleic acids; Circulating tumor cells; Micrometastasis; Minimal residual disease; surgical oncology; C; Oncology; Gynecology; Surgical Oncology; Pathology; Cancer Research; Oncology; Gynecology; Cancer Therapy; Pathology; Cancer Biology; Medicine; Gynäkologie und Geburtshilfe; Pathologie; BB

Minimal residual disease and circulating tumor cells in breast cancer: Open questions for research.- Minimal residual disease and breast cancer metastasis.- Self-seeding in cancer.- Microenvironments dictating tumor cell dormancy.- Technologies for circulating tumor cell (CTC) and disseminated tumor cell (DTC) detection and characterization.- Immunomagnetic separation technologies.- Microfluidic technologies for the isolation of CTCs.- EPISPOT assay: Detection of viable disseminating tumor cells in solid tumor patients.- Advances in optical technologies for rare cell detection and characterization.- Size-based enrichment technologies for circulating tumor cell (CTC) detection and characterization.- Emerging technologies for CTC detection based on depletion of normal cells.- Molecular assays for the detection and characterization of CTCs.- Multiplex molecular analysis of CTCs.- Other blood-based biomarkers.- Circulating DNA and next generation sequencing.- Circulating microRNAs as non-invasive biomarkers in breast cancer.- Circulating endothelial cells and circulating endothelial progenitors.- Disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in breast cancer clinical research and practice.- Bone marrow DTCs.- CTCs in primary breast cancer.- CTCs in early breast cancer.- CTCs in metastatic breast cancer.- HER2-positive DTCs/CTCs in breast cancer.- DTCs and CTCs in breast cancer – 5 decades later.- Drug and circulating tumor cell co-development.- Challenges in drug and biomarker co-development.- Challenges and opportunities in the use of CTCs for companion diagnostic development.

Provides up-to-date information on topical issues concerning minimal residual disease in breast cancer patients

Appraises the technologies available for detection and characterization of circulating and disseminated tumor cells (CTCs/DTCs)

Discusses the relevance of CTCs and DTCs in breast cancer clinical research and practice, and the role of other blood-based biomarkers

Includes supplementary material: sn.pub/extras

Provides up-to-date information on topical issues concerning minimal residual disease in breast cancer patients

Appraises the technologies available for detection and characterization of circulating and disseminated tumor cells (CTCs/DTCs)

Discusses the relevance of CTCs and DTCs in breast cancer clinical research and practice, and the role of other blood-based biomarkers